Table 1.

Patient characteristics

Characteristics	Values
Number of patients (n)	115
Number of LM	150
Gender (n)
Male	59 (51.3%)
Female	56 (48.7%)
Age at SBRT (median, range) [years]	66.1 (34.7–86.1)
Primary entities
Rectum	16 (13.9%)
Colon	38 (33.0%)
Colon ascendens	4 (10.5%)
Colon transversum	1 (2.6%)
Colon descendens	2 (5.3%)
Coecum	3 (7.9%)
Left/right flexure	3 (7.9%)
Sigma	16 (42.1%)
Unknown	9 (23.7%)
Esophagus/AEG/stomach	12 (10.4%)
Mamma Ca	20 (17.4%)
NSCLC	5 (4.3%)
Pancreas	4 (3.5%)
Ovary	4 (3.5%)
Others	16 (13.9%)
Symptoms
Present	8 (7.0%)
Absent	107 (93.0%)
KPS
100%	6 (4.0%)
90%	83 (55.3%)
80%	46 (30.7%)
≤ 70%	15 (10.0%)
Location of LM
Left lobe	46 (30.7.4%)
S1	9 (19.6%)
S2	6 (13.0%)
S3	8 (17.4%)
S4	24 (52.2%)
S4a	12 (50.0%)
S4b	4 (16.7%)
Unknown	8 (33.3%)
Right lobe	75 (50.0%)
S5	13 (17.3%)
S6	14 (18.7%)
S7	27 (36.0%)
S8	21 (28.0%)
Overlap	26 (17.3%)
Border S1/S8	1 (3.8%)
Border S2/S3	6 (23.1%)
Border S2/S4a	1 (3.8%)
Border S4a/S4b	2 (7.7%)
Border S4a/S8	6 (23.1%)
Border S5/S6	2 (7.7%)
Border S5/S8	1 (3.8%)
Border S6/S7	2 (7.7%)
Border S7/8	5 (19.2%)
Unknown	3 (2.0%)
Controlled primary
Yes	103 (89.6%)
No	12 (10.4%)
LM diagnosis
Synchronous	35 (23.3%)
Metachronous	115 (76.7%)
Metastases in other sites
Yes	58 (50.4%)
No	57 (49.6%)
Systemic therapy within four weeks before/after RT
Yes	38 (33.0%)
No	77 (67.0%)
FU-time (median, range) [months]	11.4 (0–123.3)

LM = liver metastasis; SBRT = stereotactic body radiation therapy; AEG = adenocarcinoma of esophagogastric junction; NSCLC = non-small-cell-lung-cancer; KPS = Karnofsky Performing Score; FU = follow-up; synchronous ≤3 months after initial primary diagnosis; metachronous > 3 months after initial primary diagnosis